Gantenerumab for Alzheimer's Disease
Also known as: RO4909832
A fully human anti-amyloid antibody that achieved significant plaque clearance but failed to demonstrate clinical outcomes in Phase III, raising questions about the amyloid hypothesis.
Mechanism of Action
Gantenerumab binds both the N-terminal and mid-domain of aggregated amyloid-beta, targeting both plaques and oligomers. It recruits microglia for phagocytic clearance through Fc receptor engagement. Subcutaneous administration allows higher dosing than early IV trials.
General mechanism: Fully human anti-Aβ antibody targeting N-terminal and mid-domain epitopes. Microglial phagocytic clearance.
Current Evidence
GRADUATE I and II Phase III trials failed to meet primary endpoints despite significant amyloid reduction. This highlighted the disconnect between plaque clearance and cognitive benefit, suggesting that amyloid may be necessary but not sufficient for Alzheimer's progression.
Clinical Status: Phase III completed but not approved. Development discontinued for Alzheimer's. Informative for the field regarding the amyloid-clinical outcomes relationship.
Safety Profile
ARIA similar to other anti-amyloid antibodies. Injection site reactions with subcutaneous administration.
Key Research Questions
- Why did significant plaque clearance not translate to measurable clinical outcomes?
- Does the timing of intervention (early vs. late disease) explain the disconnect?
- Can combination with tau-targeting therapies rescue the amyloid approach?